Clinicopathological Features and Management of Cancers in Lynch Syndrome

Abstract EN

Lynch syndrome (LS) is characterized by an autosomal dominant inheritance of the early onset of colorectal cancer (CRC) and endometrial cancer, as well as increased risk for several other cancers including gastric, urinary tract, ovarian, small bowel, biliary tract, and brain tumors.

The syndrome is due to a mutation in one of the four DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2.

The majority of LS patients and families can now be identified, and the underlying mutation detected using genetic diagnostics.

Regular surveillance for CRC and endometrial cancer has proved beneficial for mutation carriers.

However, screening for other tumors is also recommended even though experiences in the screening of these tumors is limited.

Prophylactic colectomy, prophylactic hysterectomy, and bilateral salpingo-oophorectomy may be reasonable options for selected patients with LS.

This paper describes the features and management of LS.